Recombinant Anti-CD38 x Anti-CD59 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD38 specificity or anti-CD59 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can recruit complement to tumor cells. It is designed for the research of Multiple myeloma (MM); Hematologic malignancies therapy.
scFv-based Bispecific Fragments
FuncS; Promising therapeutic agent
Multiple myeloma (MM); Hematologic malignancies
CD38; Cluster of differentiation 38; CD38 molecule; ADPRC1; ADPRC 1; Cyclic ADP ribose hydrolase
CD59; CD59 molecule, complement regulatory protein; 1F5; EJ16; EJ30; EL32; G344; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; 16.3A5; HRF-20; MAC-IP; p18-20; CD59 glycoprotein; protectin; 1F5 antigen; MEM43 antigen; Ly-6-like protein; T cell-activating protein; human leukocyte antigen MIC11; lymphocytic antigen CD59/MEM43; 20 kDa homologous restriction factor; membrane inhibitor of reactive lysis; membrane attack complex inhibition factor; membrane attack complex (MAC) inhibition factor; surface anitgen recognized by monoclonal antibody 16.3A5; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)
Our services and products are only for lab research, not for any diagnostic or therapeutic use.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email